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Protein Tyrosine Phosphatase 1B (PTP1B) is best known for its role in insulin and leptin signalling. Its ability to 
directly dephosphorylate the insulin receptor (IR) has made it a prime target for the development of 
anti-diabetic drugs. In recent times the role of PTP1B has been substantially expanded from a simple regulator 
of insulin signalling to a complex and dynamic regulator of multiple signalling pathways including the Janus 
kinase and signal transducer and activator of transcription (JAK-STAT) signalling, thus providing a link 
between metabolism and inflammation. Here, we review the inflammation associated with obesity and diabetes 
and the role that PTP1B may play in the development and regulation of this inflammation. We will discuss the 
role of PTP1B in both the innate and adaptive immune system and how the development of tissue specific knock 
out models have allowed us to delineate this complex system. Finally, we discuss how this new knowledge may 
allow us to develop safe and effective treatments for a multitude of conditions, including type 2 diabetes mellitus 
(T2DM), autoimmunity, and chronic inflammation. 
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Obesity induced inflammation is the main risk factor for 
development of Type 2 Diabetes Mellitus 
Type 2 Diabetes Mellitus (T2DM) is a metabolic disorder 
characterised by hyperglycaemia and hyperinsulinaemia, 
most commonly associated with being overweight or obese. 
Incidences of T2DM have increased greatly over the last 
twenty years. In 1996 within the United Kingdom alone the 
number of people diagnosed with T2DM was 1.4 million. 
This has risen steadily, reaching 3.2 million in 2013 (6% of 
the population) and it is estimated that, by 2025, 5 million 
people within the UK will have been diagnosed with T2DM 
[1], this rise in prevalence is not specific to the UK and is 
mirrored across all developed countries. Recent evidence has 
now demonstrated systemic obesity-induced inflammation to 
be the main risk factor for development of T2DM [2], 
alongside a number of other serious health problems such as, 
cardiovascular disease and stroke. This increase in incidences 
is thought to be due to a combination of a rapidly aging 
population and an increase in prevalence of obesity. 
Therefore, understanding of how T2DM is promoted and 
exacerbated is fundamental in the fight against the world’s 
most prevalent metabolic disorder.  
The highest risk factor for the development of T2DM is 
obesity, a complex disorder which can be defined as an 
expansion of the white adipose tissue due to increased 
adipocyte number and size [3]. By 2050, obesity is predicted 
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to affect 60% of the adult population [4] and now represents a 
pandemic health problem. Recent research has extensively 
shown obesity to correlate with a chronic state of sub-acute, 
low-grade inflammation, possibly owing to the intersection 
that exists between the metabolic and immune pathways [2]. 
The hypothesis of a link between inflammation and 
metabolic disease was first proposed over a century ago due 
to the observation that the anti-inflammatory drug salicylate 
(aspirin) exerted beneficial effects on glucose homeostasis in 
diabetic patients [5]. However, with the discovery of insulin 
this hypothesis become less popular, only to re-emerge in 
recent years, due to a flagship paper published by Pickup and 
Crooks which correlated inflammatory cytokines with insulin 
resistance [6], and inflammation once again became thought 
of as a root cause of T2DM.  
Homeostatic environment of the adipose tissue is 
maintained by M2 macrophages 
Obesity is associated with a significant number of 
differentially regulated genes, including adipokines, 
cytokines and enzymes involved in lipid metabolism. 
Adipose tissue is comprised of a number of cell types, from 
pre-adipocytes, adipocytes, vascular epithelial cells to a 
number of immune cells such as macrophages, which 
infiltrate into the adipose tissue and are estimated to reach 
over 20-30 million per kilogram of excess fat [7]. Adipocyte 
tissue macrophages (ATM) are the most abundant immune 
cell type, these ATM are highly plastic cells, capable of 
adapting to different microenvironments within the tissue [7]. 
During normal homeostatic conditions in the adipose 
tissue the immune population is dominated by TH2 cells - T 
regulatory cells (Tregs) and eosinophils - which act in concert 
to induce and maintain an anti-inflammatory environment. 
Eosinophils produce IL-4 and IL-13 [8], whereas resident 
macrophages and Tregs primarily release IL-10 [9]. The 
displayed phenotypes of macrophages can exist anywhere 
upon a sliding scale between the M2 anti-inflammatory side, 
under normal homeostatic conditions to highly polarised M1 
pro-inflammatory ATM. 
Homeostatic ATM are typically IL-10high and IL-12low, 
Figure 1. Immune cells mediate inflammation in adipose tissue. In obesity-induced 
inflammation, monocytes are recruited to the adipose tissue via chemoattractants initially secreted 
by the adipocytes themselves. The pro-inflammatory response is further reinforced by recruited 
CD4+ TH1 and CD8+ effector T cells and B cells, resulting in a shift of the tissue environment away 
from the homeostatic M2 end of the scale to pro inflammatory M1. 
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and are involved in immunoregulatory roles and thus lay at 
the M2 end of the macrophage polarisation scale. Indeed, not 
only do they secrete anti-inflammatory cytokines, but also a 
number of growth factors, including transforming growth 
factor beta (TGF-β), which can act as an immunosuppressant 
and regulates adipogenisis [10], along with insulin-like growth 
factor (IGF-1) [11], a hormone similar in structure to insulin 
that regulates cell growth. In particular, M2a and M2b 
macrophages (respectively induced by IL-4/IL-13 and 
combined exposure to immune complexes and Toll Like 
Receptor or Interleukin 1-Receptor agonists) orchestrate TH2 
responses. IL-10-induced M2c macrophages, instead, 
primarily function in immune suppression and tissue 
remodeling. However, it is important to stress that this 
schematic classification does not fully reflect the complexity 
of macrophage activation, and indeed macrophages can be 
seen as lying on a continuum spectrum characterised by 3 
fundamental functions, namely: host defense, wound healing 
and immune regulation [12]. 
Obesity disrupts adipose tissue homeostasis, inducing 
inflammation and insulin resistance. 
Excessive weight gain leads to the pathological expansion 
of adipocytes, the stress of lipid uptake and cell expansion in 
order for adequate lipid storage causes cellular stress. 
Eventually, cells can no longer compensate for this stress and 
a portion of adipocytes enter necrotic cell death; thus, the 
presence of these necrotic cells is considered to be one of the 
pathological hallmarks of obesity. The death of these cells 
results in a release of a plethora of cytokines and chemokines 
that induce the infiltration of immune cells, mostly 
macrophages, from the circulation [13]. These infiltrating 
macrophages form crown like structures (CLS) around the 
necrotic cells which can be easily identified by perilipin stain 
[14]. In addition, this infiltration of macrophages is associated 
with a phenotypic switch from the homeostatic M2 end of the 
scale to the pro-inflammatory M1 side [15] (Fig.1).  
This increase in ATM recruitment and the phenotypic 
switch subsequently leads to an increase in inflammatory 
cytokines which, are derived mostly from the presence of 
these M1 macrophages rather than the adipocyte cells [13]. 
Interestingly, weight loss is also associated with infiltration 
of macrophages into the tissue [16], although it is thought that 
this population is transitory in nature and display a different 
phenotype which serves to promote and regulate lipolysis 
and transcriptionally display increased levels of lipid 
metabolism genes such as apoE and fatty acid handling 
protein 4 [17]. 
This phenotypic switch results in potent activation of the 
JNK and IKKβ/NFkB pathways, which directly impairs 
insulin signalling, while also transcriptionally up-regulating 
pro-inflammatory genes, including TNF-α, IL-6 and MCP-1 
[18] (Fig. 2). Furthermore, TNF was shown to be expressed at 
very high levels in the adipose tissue of obese humans [19] 
and rodents, and antagonises the action of insulin in cultured 
cells [20]. It has been proposed that TNFα antagonises the 
action of insulin via upregulating the expression of PTP1B 
which dephosphorylates the insulin receptor (IR) and thus 
terminates the signal transduced though the receptor. This 
hypothesis has been supported by a number of studies, which 
have demonstrated that in vitro PTP1B is upregulated in 
response to TNFα treatment in multiple tissues including 
hepatic, muscle and adipose tissue [21, 22]. This was mirrored 
in vivo in mouse models where an increase in PTP1B 
expression was observed in a number of tissues during 
inflammation; again including adipose and hepatic tissues 
[21]. 
Additionally, it has been demonstrated that in vivo, PTP1B 
can be upregulated via TNFα [23] and furthermore, that high 
fat diet (HFD) feeding of mice leads to a concomitant 
increase in both TNFα and PTP1B levels [2]. These findings 
were further supported by studies from clinical settings, 
demonstrating that T2DM patients exhibit high expression 
Figure 2. Activation of the IKKβ and NFκB signalling results in 
induction of inflammatory genes. The canonical NFκB pathway is 
induced by a wide variety of signals such as Toll Like Receptors 
(TLR4 is shown as an example) and a number of cytokines. 
Induction of the pathway involves a number of adaptors (not shown) 
which cause phosphorylation of IKKβ subunit of IKK. In turn IKKβ 
phosphorylation of IκB proteins bound to NFκB leads to ubiquintation 
of the IκB proteins leaving NFκB free to translocate into the nucleus 
of the cell. In the nucleus NFκB binds the DNA at specific sequences 
called κB sites and controls the transcription of inflammatory genes.   
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levels of PTP1B [24]. It may be proposed that this 
upregulation of PTP1B, leading to disruption in insulin 
signalling in response to obesity-induced inflammation, may 
be an important mechanism by which insulin resistance and 
T2DM develops.  
Generally, this inflammatory response is acute, and the 
associated hyperlipidemia and enhanced catabolism is only 
transient in nature. Indeed, the changes in insulin sensitivity 
and maintenance in glycaemia during acute inflammation 
may be of benefit, by diverting glucose away from tissues 
and into the blood stream, making it more available to the 
immune system during a response to neutralise challenges [25]. 
However, a continually expanding body of evidence supports 
the idea that disturbance in metabolic homeostasis can induce 
immune imbalance on a continuous spectrum that has 
immunosuppression and undernutrition at one end, and 
over-nutrition, obesity and sustained inflammation at the 
other. In this context, T2DM can be seen as an 
obesity-associated inflammatory disease. 
Indeed, in all metazoans, the metabolic and immune 
pathways have evolved to be intimately connected and 
intrinsically overlapping, with a significant number of shared 
key molecules. In most cases, this integration is beneficial 
for the organism, as the normal inflammatory response is 
dependent on the mobilisation of stored energy [25]. 
The expansion of PTP1B’s role from insulin signalling to 
the immune system 
PTP1B, in humans is encoded by the ptpn1 gene, is a 
ubiquitously expressed, non-receptor, tyrosine phosphatase 
which is located on the cytoplasmic face of the endoplasmic 
reticulum (ER) [26]. It was the first tyrosine phosphatase 
discovered and was first isolated from human placenta [27] 
before being identified in all tissues [28]. More recently, the 
role of PTP1B has been expanded from being a simple 
regulator of insulin signalling to a multitude of substrates.  
PTP1B has been well characterised as the master regulator 
of insulin signalling, where it dephosphorylates the insulin 
receptor (IR) resulting in a blockade of insulin signalling 
(Fig. 3), leading to insulin resistance and the development of 
hyperglycaemia [29]. PTP1B deficient mice display increased 
sensitivity to insulin and insulin dependent IR 
hyperphosphorylation; they also exhibit resistance to HFD 
induced obesity and have lower levels of adiposity [30]. 
Additionally, tissue specific knock out models of PTP1B 
(neuronal [31], hepatic [32] and muscle [33]) have all shown 
positive effects on metabolism indicating PTP1B could be a 
critical therapeutic target for T2DM treatment.  
The dephosphoylation of pTyr by PTP1B is executed via a 
two-step mechanism; the first step involving neutrophilic 
attack of the phosphocenter by the reduced Cys215 residue, 
followed by subsequent protonation of Asp181 to yield the 
neutral tyrosine phenol. The thiophosphate intermediate is 
then hydrolysed and the enzyme is regenerated [34]. The 
development of substrate trapping mutants was a critical step 
in the identification of its targets. Specifically,  mutation of 
the invariant Asp181 residue prevents the completion of the 
neutrophilic attack portion of the dephosphorylation process, 
effectively ‘trapping’ the substrate in a stable complex with 
the enzyme, thereby allowing the mutant PTP1B-D181A and 
its trapped substrate to be co-immnoprecipitated [35]. There 
are now several examples of substrate trapping mutants 
including PTP1B-Q262A, PTP1B-D181A-Q262A [36], and 
PTP1B-C215D [37]. It is through these approaches that 
molecules such as epidermal growth factor receptor (EGFR) 
[38], JAK 2, TYK2 [39], STAT3 [40], STAT6 [41], and many 
more have all been identified as PTP1B substrates and, in 
doing so, placing more focus on the importance of role of 
PTP1B in inflammation.  
Role of PTP1B in development of inflammation in global 
knock out models 
Figure 3. Protein Tyrosine Phosphatase 1B directly 
dephosphorylates the insulin receptor resulting in blockade of 
insulin signalling. In response to insulin ligation, the insulin 
receptor (IR) is phosphorylated and recruits multiple downstream 
targets; including insulin receptor substrates (IRS) and GBR2. In turn 
phosphorylation of IRS recruits phosphatidylinositol 3-kinase (PI3K) 
through binding of the p85 subunit which causes activation of the 
catalytic p110 subunit. PI3K causes activation of the downstream 
AKT pathway and leads to induction of metabolic effects such as 
glucose uptake into muscle and induction of lipid metabolism. GBR2 
leads to activation of the mitogen-activated protein kinase (MAPK) 
pathway leading to downstream activation of genes which facilitate 
cell growth and proliferation.  
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PTP1B has a complex role in the immune system which 
has not yet been fully characterised. Indeed, it is thought to 
be important in many areas ranging from haematopoiesis and 
macrophage polarization [42], regulation of dendritic cell 
(DC)[43]function and macrophage [44-46] function to the 
induction of B and T-Cell tolerance [47] in the periphery. 
During development of the myeloid lineages, PTP1B is 
involved in myelopoiesis since PTP1B deficiency altered 
signalling in response to colony stimulating factor 1 (CSF-1), 
via the JAK2/STAT3 pathway, subsequently resulting in a 
skewed ratio between monocytes and granulocytes in vivo. 
This bias is thought to be due to a combination of decreased 
threshold in response to MCSF and the 
hyper-phosphorylation of the activation loop tyrosine in 
PTP1B. Interestingly, it was demonstrated that this 
phenomenon was specific to the granulocyte-monocyte 
precursor stage, as this was not present at earlier stages of 
bone marrow differentiation. It was also reported that the 
resulting bone marrow derived macrophages (BMDM) 
exhibited an increase in sensitivity to endotoxin and 
upregulation of inflammatory markers, both in vitro and in 
vivo, providing evidence that PTP1B is a negative regulator 
of inflammation [42].  
Global deletion of PTP1B has been shown to produce 
significant pro-inflammatory phenotype [48], splenic 
macrophages isolated from global PTP1B deletion models 
showed increased pro-inflammatory activity [49], additionally, 
in vitro knock down of PTP1B in RAW.264.7 cell line led to 
increased production of TNF-α, IL-6 and IFN-γ in response 
to LPS challenge [50]. This was corroborated in another study 
that reported similar results in peritoneal macrophages from 
global deletion model along with PTP1B knock downs in 
human macrophages from donors and cell lines [44]. Logically, 
it was hypothesised given macrophages importance in the 
development of T2DM and obesity, and the heightened 
inflammatory response, that macrophage specific PTP1B 
may be an important factor in the induction of insulin 
resistance and hence cell-specific targeting of PTP1B would 
be advantageous in the treatment of T2DM.  However, 
myeloid specific deletion of PTP1B produced a pronounced 
anti -inflammatory phenotype, directly contradicting what 
was observed in global knock out, while maintaining the 
improvement in both, glucose homeostasis and resistance to 
the development of T2DM [46]. However, no changes in 
inflammation were detected in either muscle [33] or adipocyte 
[51] specific PTP1B deletion models, whereas modest 
improvement in liver inflammation was reported in the liver 
specific knock out models[32]. 
Myeloid cell PTP1B model reveals a role for PTP1B in 
the promotion of inflammation 
When analysing the role of PTP1B, it is of critical 
importance to consider the methods by which its function has 
been studied. PTP1B appears to display cell and tissue 
specific roles, differing in its signalling roles between 
different cell and tissue types. Thus, creation of cell-type 
specific PTP1B knockout models has been invaluable in our 
understanding of the specific roles that PTP1B plays in 
different tissues. Using these collective results and 
comparing to the global knock out model combined with cell 
line studies, we can begin to untangle the complicated 
function(s) of PTP1B in inflammation and the immune 
system.  
When compared to control littermates, myeloid specific 
deletion of PTP1B (LysM PTP1B) mice were resistant to 
LPS-induced endotoxaemia and HFD induced inflammation. 
Furthermore, elevated systemic IL-10 levels with a 
corresponding decrease in IL-6 was observed, which was in 
agreement with the in vitro data, indicating that bone marrow 
derived macrophages (BMDM) release lower levels of 
pro-inflammatory cytokines and increased IL-10 [46]. DC are 
also myeloid cells derived from the same cell lineage as 
macrophages, bone marrow derived DC from the LysM 
PTP1B model display defects in several key functions 
namely, LPS driven activation, presentation of peptide to T 
cells and their subsequent activation, along with a decrease in 
migratory capacity [43]; the ramifications of which leads to 
modulation of the adaptive immune system. More 
specifically, LysM PTP1B BMDC lack the ability to fully 
initiate T cell responses, and this, coupled with IL-10[46] 
increases seen in the macrophages, may act in an 
immunosuppressive manner to quash inflammatory 
responses and hence produce the heightened 
anti-inflammatory response seen in this model.  
Both BMDM and BMDC from the LysM PTP1B model 
have been shown to have hyperphosphorylation of STAT3, 
which is concurrent with PTP1B deletion after day 4 in 
culture in BMDC [43]. One of the few immune consistencies 
between the global and tissue specific PTP1B knock-out 
models is the hyper-phosphorylation of STAT3. Treatment of 
peritoneal macrophages from the global knock out with 
IL-10 leads to hyper-phosphorylation of STAT3, resulting in 
a qualitative change in the transcriptome downstream and 
induced genes associated with inflammation [45]. This 
suggests that PTP1B plays a role in the promotion of 
inflammation via STAT3, rather than negatively regulating it 
as previously thought, which would be more consistent with 
the improved metabolic profile than a negative regulatory 
role.  
Finally, it is important to consider the differences in 
PTP1B deletion between these models.  In the LysM 
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PTP1B model, PTP1B is excised via the LoxP-Cre system 
when Lysozyme-M gene is activated [52], whereas, in the 
global knock out, PTP1B is absent during the entire 
differentiation process, while it is known this alters the ratio 
of monocytes to granulocytes as previously discussed, it is 
currently unknown if this directly alters the immune 
phenotype. The possibility that the absence of PTP1B during 
the differentiation process has intrinsically altered the 
functionality of these cells cannot be discounted.  
B cell PTP1B deficiency may account for discrepancies 
between myeloid and global knock out models 
As mentioned previously, PTP1B is ubiquitously 
expressed and is also present in cells of the adaptive immune 
system. B cell PTP1B has been shown to play a critical role 
in the activation of B cells and the maintenance of 
immunological tolerance. PTP1B in B cells was 
demonstrated to negatively regulate TLR-4 signalling and B 
cell activating factor receptor (BAFF-R) signalling, which is 
important for B cell survival. Furthermore, PTP1B is 
involved in CD40 signalling, which is involved in the 
interaction with CD4+ T Cells prompting the switch to 
production of high affinity IgG antibodies [47].  
The mb1-PTP1B model specifically deletes PTP1B in B 
cells. Deficiency of PTP1B in these cells results in an 
augmented response to LPS, which induces abnormal 
proliferation and differentiation into plasma cells. This is 
consistent with peripheral autoreactive B cells, which have a 
lower threshold for response and differentiate into 
self-reactive plasma cells [47]. Indeed, there is evidence to 
support this hypothesis as B cells from patients who suffer 
from rheumatoid arthritis appear to have lower levels of 
PTP1B. These cells behave consistently with those from the 
mb1-PTP1B model and display heightened responses to 
inflammatory stimuli [47] and therefore may account for the 
heightened inflammatory response seen in the global knock 
out models.  
T cell - Protein Tyrosine Phosphatase (TC-PTP) is a close 
relative to PTP1B and is expressed mainly in T Lymphocytes. 
It is thought to play a similar role to PTP1B as it is able to 
directly dephosphorylate IR in T cells, this was confirmed 
through double PTP1B and TC-PTP knock out cell line 
studies which illustrated the non-redundant role of both 
proteins in insulin signaling [53]. It has also been 
demonstrated that TC-PTP lowers the threshold for T cell 
signalling, leading to autoimmunity and proliferation of cells. 
Thus, it is thought that TC-PTP mirrors the role of PTP1B 
Table 1. Summary of PTP1B and TCPTP global and tissue specific knock out models in 
mice. Observed phenotypes in murine knock out models of PTP1B and TCPTP are not 
consistent, though this may not be surprising given PTP1B’s differing roles in different 
tissues. Global, hepatic, neuronal, muscle and myeloid knockout models all exhibit increased 
glucose and insulin sensitivity with the myeloid and hepatic models offering protection 
against inflammation. Global and B cell PTP1B knock outs and the T cell TCPTP knock out 
all confer an increase in inflammation and increased disease. Therefore it would be logical to 
hypothesize that the increase in inflammation in the global model may be a consequence of 
PTP1B deficiency in B cells or possibly, T cells. 
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and negatively regulates T cell induced inflammation [54]. 
Given that PTP1B and TC-PTP are thought to have a similar 
role and also share substrates, delineating the PTP1B specific 
roles in T cells is a complex matter, further muddied by fact 
that PTP1B T cell specific knock outs have not yet been 
published. However, given the interest in PTP1B and the 
immune system it is a keen and exciting area of research that 
is fast developing.  
While the phenotypes of the discussed models may appear 
contradictory (summarised in table 1) they give us valuable 
insight to the role PTP1B plays in individual tissues. The 
pro-inflammatory phenotype seen in the global PTP1B knock 
out is most likely a result of PTP1B deficiency in the B cells 
- or T cells if PTP1B plays a similar role as TCPTP as 
hypothesised - leading to a systemic increase in inflammation 
which modulates the tissue environment, causing a 
phenotypic switch of macrophages to a M1 profile, rather 
than an intrinsic PTP1B deficiency in the macrophages 
themselves as previously thought.  
Inhibition of PTP1B as a treatment for chronic 
inflammatory disorders 
Given the importance of PTP1B both in the regulation of 
inflammation and insulin signalling, inhibitors of PTP1B 
have become a focused area of interest in drug discovery 
research. There are already several well-known small 
molecule inhibitors of PTP1B that are routinely used in the 
lab to study PTP1B both in vitro and in vivo which are made 
and distributed by multiple biotechnology companies for use 
in research.  Many inhibitors (at least in vitro) have been 
discovered from a number of biological sources, such as 
polybromodiphenyl ether from an Indonesian marine sponge 
Lamellodysidea herbacea [55], multiple compounds in 
Angelica kesikei [56], a well-known anti-diabetic plant used in 
Japanese medicine as well as phylogenetic and 
computational methods and rational design approaches [37], 
all with the aim to develop small molecule inhibitors of 
PTP1B.  
Designing PTP1B inhibitors is particularly difficult, due to 
the highly positively charged active site pocket and the fact 
PTP1B shares close homology with several other PTPs such 
as the aforementioned T-Cell PTP (TC-PTP). Thus creating a 
specific small molecular inhibitor which can be given via an 
oral route with desirable physiochemical properties, that is 
both efficacious in vivo and safe is a tremendous task. 
However, it is the nature of drug discovery that most 
compounds found to have the desired effect in vitro will fail 
during development and, to date, no compounds have 
successfully completed all phases of human clinical trials. As 
such, none have been licenced for use in the clinic due to 
lack of in vivo efficacy; however there are small molecule 
inhibitors currently in phase II clinical trials.  
While PTP1B inhibitors could be of great use in treatment 
of T2DM and chronic inflammatory disorders, care must be 
taken. As previously discussed, modulation of PTP1B in 
immune cells can greatly upset the homeostatic balance of 
the immune system. While clearly the over expression of 
PTP1B that creates insulin resistance is detrimental, equally, 
the absence of PTP1B in certain cell types such as B Cells 
can cause deleterious effects and exacerbate inflammation. 
Therefore an approach where excessive PTP1B is inhibited 
and returned to a baseline level in order to restore 
homeostasis would be the most beneficial in terms of 
treatment regimes. However this presents its own challenges, 
polymorphisms in genes encoding metabolising enzymes and 
drug transporters can affect the pharmokinetics and alter drug 
response. Dosages given to patients would have to be closely 
monitored in the clinic and tailored individually for the 
patient taking into account these factors, meaning a 
personalised approach would have to be taken bringing into 
question the cost-effectiveness of use of PTP1B inhibitor in 
the general population. Another approach may be the 
development of cell type specific delivery systems for a 
PTP1B inhibitor, inhibition of myeloid PTP1B would be 
highly advantageous and help minimise side effects 
associated with inhibition in B cells.  
Concluding Remarks 
In all metazoans, the mechanisms responsible for defence 
against pathogens have been evolutionarily coupled to 
metabolic control, with the aim of ensuring adequate host 
response to bacterial and viral pathogens, while subsequently 
preventing excessive inflammation that would lead to tissue 
damage. Metabolic homeostasis is the result of a delicate 
balance determined by the interplay of multiple factors. In 
particular, the functional cross-talk between adipocytes and 
resident M2-like macrophages ensures maintenance of 
insulin sensitivity; this is mostly mediated by signalling of 
anti-inflammatory cytokines like IL-4, IL-10 and IL-13. 
The immune imbalance caused by nutritional overload can 
lead to chronic inflammatory status that is causal in the 
development of insulin resistance and hyperlipidemia. 
PTP1B, the master regulator of insulin signalling, forms a 
bridge between metabolism and inflammation and is a potent 
target for drug development. While its role is complex, 
multifactorial, cell type specific and often contradictory, 
however, by examining tissue specific knock outs we can 
delineate aspects of its complex role.  
While global knock out models show improvement in 
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glucose homeostasis, this is accompanied by escalation of the 
LPS induced inflammatory response. In muscle, neuronal [31] 
and adipocyte specific [51] models this indicate no changes in 
inflammation, with hepatic specific [32] deletion offering 
some protection against liver inflammation. This led to the 
speculation that the pro-inflammatory phenotype observed 
with global PTP1B deficiency may be caused PTP1B 
absence from the immune cells. 
LysM PTP1B model revealed enhanced anti-inflammatory 
properties, with a decrease in IL-6 and an increase in IL-10 
both systemically and in vitro, coupled with decrease in 
BMDC migratory capacity and in capacity to activate T cells. 
A combination of inadequate migration and peptide 
presentation with a systemic anti-inflammatory environment 
may be working synergistically to supress the inflammatory 
responses. Consistently, across these models, STAT3 appears 
to be hyper-phosphorylated, indicating that the regulation of 
inflammation by macrophage and DC PTP1B is 
STAT3-dependent. The differences in these models point to 
speculation that PTP1B may have an effect on the 
polarisation of macrophages during development as it is also 
known to have a key role in haematopoiesis [42]. Evidence 
from the B cell specific deletion model mb1-PTP1B, 
suggests a highly pro-inflammatory phenotype due to PTP1B 
deficiency in B cells, along with development of 
autoimmunity, an observation echoed in human rheumatoid 
arthritis patient B cells [47]. This closely matches observations 
in the global knock out models and may account for the 
pro-inflammatory phenotype observed including some of the 
autoimmune aspects of the phenotype.  
Given PTP1B’s critical role in the regulation of 
inflammation and insulin signalling it is an important and 
critical target for the development of clinical treatments. If 
drugs are to be successful in this manner, they must be highly 
specific either in design or targeting to avoid disrupting the 
function of other closely related phosphatases and tailored 
for use in a manner that corrects the increased PTP1B 
expression associated with T2DM and obesity. While, to date, 
no inhibitors have made it through human clinical trials, 
work is ongoing apace to bring forward their use to the clinic 
and revolutionise the treatment of the world’s most costly 
and prevalent metabolic disorder.  
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